OpenNashPodcasts

Eye On A.I.

#255 Eric Topol: Why AI is the Most Powerful Tool in Healthcare Now

18 May 2025 · 48m · Eric Topol, Craig S. Smith · 25 quoted facts

▶ Play episodeOriginal source ↗

In brief

Eric Topol argues that AI can now turn deep personal data into a forecast of when an individual will develop heart disease, Alzheimer's or cancer. Because these diseases take about 20 years to develop, early warning leaves time to prevent or delay them. His book Super Agers lays out this approach, which he says is safer and closer than anti-aging drugs.

The tension is between what is possible and what is available. Topol says the AI models are good enough already, but the data is scattered across separate tests and companies, personal ownership of health data is unresolved, and the US insurance system rewards short-term thinking. Anti-aging drugs such as senolytics and reprogramming carry cancer risks and are years away.

Key insights

  1. AI can forecast when disease will strike

    Older genetic risk scores could not say whether Alzheimer's would hit at 68 or 98. Topol says combining many data layers, then repeating the measurement six months to a year later, lets AI estimate timing.

  2. Organ clocks measure aging organ by organ

    A blood sample can measure about 11,000 plasma proteins and show which organ is aging faster. Topol's example is a heart that looks seven years older than the person, which tells doctors where to focus.

  3. Genes explain less of disease than assumed

    Topol says family history is overemphasized, especially outside cancer. His Wellderly study sequenced the genomes of 1,400 people who reached age 85 and stayed free of these diseases, and found almost nothing special.

  4. Anti-aging drugs remain risky and distant

    Yamanaka-factor reprogramming can cause tumors if given systemically, so companies are testing it only in contained sites such as the knee or eye. Senolytics cannot yet tell harmful senescent cells from helpful ones.

  5. Longevity startups collect the wrong data

    Topol says firms such as Function Health, Fountain Life and Human Longevity gather many tests but not the right layers, and none have a serious AI effort. Function is valued at $2.5 billion with 50,000 members, so demand is clearly large.

Questions

Can AI really predict when I'll get Alzheimer's, heart disease or cancer?

Topol says it can estimate risk and timing by combining many data types, such as genome, proteins, metabolites and microbiome. It works best with two measurements six months to a year apart, and it is more precise for events three to five years away than 18 years away.

What is an organ clock?

It is a blood-based measure of how fast each organ is aging, built from roughly 11,000 plasma proteins. Topol says it might show, for example, that a person's heart is seven years older than their actual age.

Why can't I just get all these tests today?

Topol says the tests are piecemeal: you go to one provider for your organ clock, another for epigenetic aging, another for metabolites and another for the microbiome. The AI tool is not yet joined to those layers, though he expects companies to combine them within a year or two.

Why does Topol prefer prevention to anti-aging drugs?

He says drugs such as senolytics and cell reprogramming are years away, if they arrive at all, and can raise cancer risk. Prevention using forecasts and lifestyle changes is available now and, in his view, not risky.

Who will be able to afford this kind of forecasting?

Topol says the individual tests cost under $100 or $50 each, so the package could be cheap compared with a total-body MRI. He thinks countries with national health systems, like the UK, will adopt it before the US, where insurers focus on short-term costs and access may favor the affluent.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

Eric Topol earlier wrote The Creative Destruction of Medicine, about digital medicine, and was about to publish Super Agers, about using AI to promote healthspan.

“I wrote a book called the creative destruction of medicine which was about going digital in medicine and then most recently uh about to be published as a book called super agers”

0:01:53 · Eric Topol · Topol's books

Topol says heart disease, Alzheimer's and cancer each take about 20 years to develop and share links to the immune system and inflammation.

“they all take 20 years to incubate they all have common threads of the immune system and inflammation”

0:03:26 · Eric Topol · Age-related disease

Topol says US genetic nondiscrimination protections do not fully cover disability and life insurance, which is why he would not put genome data in electronic health records.

“we don't protect people fully for things like disability insurance and life insurance and you know various things that are not related to health insurance”

0:06:36 · Eric Topol · Genetic privacy

Topol says large language models such as GPT-4 and Llama were already well suited to medical forecasting because they had ingested the medical literature.

“the models that already were appearing like in gbt4 and and llama and others really were remarkably well suited for for this”

0:09:02 · Eric Topol · AI models

Topol says polygenic risk scores, such as those from 23andMe, give no time range for when a disease might occur.

“what if the risk is when you're 98 rather than 68? Big difference. And there was no way to be able to ascribe a time range.”

0:10:26 · Eric Topol · Polygenic risk

Topol describes the p-tau 217 blood biomarker as a major breakthrough for surveillance of neurodegeneration.

“surveillance for neurodegeneration with these new p-tower 217 biomarkers, which was a really big breakthrough.”

0:11:43 · Eric Topol · Alzheimer's biomarkers

Topol says a single blood tube can yield about 11,000 plasma proteins, which organ clocks use to estimate the biological age of individual organs.

“From a tube of blood, you can get 11 ,000 plasma proteins. It'll tell you which organ.”

0:14:54 · Eric Topol · Organ clocks

Topol cites the Horvath epigenetic clock, which reads methyl groups on DNA, as an example of a molecular aging clock.

“like the Horovath clock, where you look at methyl groups on the DNA.”

0:14:54 · Eric Topol · Epigenetic clocks

Topol says there are roughly 50 anti-aging companies, including Altos Labs, Unity and Insilico Medicine, pursuing drug approaches.

“There's 50 of these anti-aging companies, right?”

0:16:06 · Eric Topol · Anti-aging industry

Topol says Function Health was valued at $2.5 billion, with 50,000 members and a wait list.

“Function has a valuation of $2.5 billion already. It has 50 ,000 members and a wait list.”

0:25:45 · Eric Topol · Longevity startups · 2025

Topol says Neko Health had 100,000 people on a wait list.

“Neco Health has 100 ,000 people on a wait list.”

0:25:45 · Eric Topol · Longevity startups · 2025

Topol says Human Longevity, started about a decade earlier, offered total-body MRI and genome sequencing for about $25,000 and is now almost nonexistent.

“Human longevity they get total body mri and genome sequence this was before there was any ai got all these labs and whatnot that company is just basically not almost non-existent now charging 25,000”

0:24:21 · Eric Topol · Longevity startups

Topol says Function Health's Mark Hyman visited him and offered him a role with financial incentives, which he declined to avoid conflicts of interest.

“Mark Hyman. he flew here, right here sitting in my office, and he offered me to, you know, be part of the company and, you know, get all sorts of financial incentives.”

0:26:47 · Eric Topol · Conflicts of interest

Topol says he obtained the beginnings of his own immunome profile from Infinity Bio, a Johns Hopkins spinoff.

“I got uh an immunome the beginning of an immunome from a company, Infinity Bio, Johns Hopkins spinoff”

0:28:55 · Eric Topol · Immunome

Topol says two measurements taken six months to a year apart can show the pace of amyloid buildup, early cancer and artery plaque.

“if you have just two points on the curve uh you'll know what's about the brain amyloid accumulation what about microscopic cancer showing up what about atheroma forming in arteries”

0:30:25 · Eric Topol · Risk timing

Topol says Mass General Brigham uses a top 5 to 10 percent cutoff to define high genetic risk.

“That's where some medical health systems, like for example, Mass General Brigham has drawn the threshold for genetic risk.”

0:31:45 · Eric Topol · Genetic risk

Topol says that when multi-cancer early detection tests are given to everyone aged 50, about 995 of every 1,000 people test negative, and that adding risk information would raise the yield.

“You know, out of 1000 people that get the test now, 995 are negative.”

0:32:56 · Eric Topol · Cancer screening

Topol says the Wellderly study at Scripps sequenced the genomes of 1,400 people who lived past 85 without these diseases and found very little special in their genes.

“We did a so called WELDERLY study, we called it here. 1400 people lived through past age 85, never sick.”

0:34:43 · Eric Topol · Wellderly study

Topol says Demis Hassabis and Geoffrey Hinton have both said improving health will be AI's most important use, and that they endorsed his book along with Mustafa Suleyman.

“both Demis and Jeff have said that the most important ever use of AI will be to improve our health.”

0:21:56 · Eric Topol · Book endorsements

Topol says brief exposure to Yamanaka factors can make an old mouse young, but giving them to humans risks tumors, so companies are testing them in the knee and the eye.

“many companies are pursuing the yamanaka factors right and you know you brief exposure to them and you can turn a an old mouse into a young mouse”

0:41:02 · Eric Topol · Cellular reprogramming

Topol says senolytic drugs cannot yet distinguish harmful senescent cells from helpful ones, and some such approaches induce cancer in some organisms.

“they can't tell the good senescent cells from the bad senescent cells.”

0:13:41 · Eric Topol · Senolytics

Topol says he was asked to review the UK National Health Service, and expects countries with national systems to adopt preventive forecasting before the US.

“I was asked to review the national health service in the uk they're representative of most other uh rich countries”

0:45:09 · Eric Topol · Health systems

Topol says each of the additional data-layer tests costs under about $100, far less than a total-body MRI, which costs thousands.

“every one of these is, you know, it's below $100, $50, you know.”

0:45:09 · Eric Topol · Test costs

Craig Smith describes the Model Context Protocol as an Anthropic-developed standard for connecting AI systems to different data sources and tools.

“Anthropic developed standard protocol for connecting AI systems to disparate data sources or disparate tools sort of thing.”

0:17:33 · Craig S. Smith · Model Context Protocol

Topol names Metabolon as a company that measures a person's metabolome.

“there's a company, Metabolon, that does that and other companies as well.”

0:18:59 · Eric Topol · Metabolomics

Chapters

  1. 0:03:26Topol's background and the Super Agers thesis

    Topol introduces his digital medicine career and argues that the three big age-related diseases incubate for 20 years, leaving time to act.

    “they all take 20 years to incubate they all have common threads of the immune system and inflammation”
  2. 0:08:07Data ownership and why models aren't the bottleneck

    Topol says people should own their health data and that current multimodal AI models are already good enough, so access to data is the real obstacle.

    “So the models are not the holdup. The data ownership is actually an issue that has to be grappled with.”
  3. 0:11:03Precision medical forecasting and timing risk

    He contrasts old polygenic scores with layered data that can place a risk in time, and describes tests such as multi-cancer blood tests and p-tau217.

    “you can give a person's projection in time when this is going to be an issue if they don't do anything about it.”
  4. 0:16:06Organ clocks versus anti-aging drug bets

    Topol explains that organ clocks, not drugs, are the main outcome of aging science, and that drug approaches are risky and distant.

    “But I have a different plan that's not risky, okay?”
  5. 0:25:10The longevity company landscape

    He assesses companies such as Function Health and Human Longevity and explains why he refuses advisory roles.

    “none of them are getting the right data.”
  6. 0:30:25Predicting timing and the limits of genetics

    Topol explains how two measurements pin down timing and why family history and genes are overrated, citing the Wellderly study.

    “two data points separated in time by six months or a year, and you nailed it.”
  7. 0:38:52Precision medicine, reprogramming and senolytics

    Topol says precision medicine has largely disappointed so far and that reprogramming and senolytic therapies carry real risks.

    “precision medicine largely has been a disappointment it's been talked about a lot but we haven't achieved it”
  8. 0:44:33Healthspan, cost and equity

    The conversation ends on whether longer lives strain resources, the low cost of the tests and why other countries may adopt them first.

    “the desire really isn't for lifespan. It's for healthspan, right?”

Transcript

0:00:00
Eric Topol

Now things are different. First of all, you have all these different layers that are orthogonal, that back up each one, you know, from another, looking to the same try to forecast. I call it precision medical forecast. Like the weather forecasting, AI is completely revamping that, making it at accuracy levels that are hard to fathom how great it will be. The same thing is true here. So basically the difference is you've got all these additional layers of data we didn't have.

0:00:25

And what's really noteworthy is you can give a person's projection in time when this is going to be an issue if they don't do anything about it. About the science of aging, it's not about the drug. It's about being able to clock a person, a person and their organ systems, including their immune system. We never had that before. That's what's different right now. AI is everywhere right

0:00:46
Speaker 3

now, but with all the buzz, how do you cut through the noise and focus on what really matters? If If you're looking to dive deep into the big questions shaping AI's role in business today, you need to tune in to Where AI Works. Conversations at the Intersection of AI and Industry, brought to you by the Wharton School in collaboration with Accenture. Each episode cuts through the hype, blending cutting-edge research from Wharton professors with real-world case studies.

0:01:12

You'll discover how leading companies are leveraging AI to upskill their teams, boost productivity, and streamline operations. And you will hear directly from executives and industry pioneers who are implementing AI in their businesses today. No fluff, just practical insights. Listen to Where AI Works Now on your favorite podcast app and get the strategies that matter most for today's business leaders.

0:01:39
Craig S. Smith

introduce yourself to listeners uh obviously you're a doctor but how you got so deeply involved in the tech space and what your book is about and then we'll talk about that well i'm dr eric

0:01:53
Eric Topol

topel i am a professor and edp at scripts research in la jolla california i've been involved from the earliest days of digital medicine back in the 90s with biosensors with smartphones connected to the internet even before there was a real digital infrastructure so back you know many years ago i wrote a book called the creative destruction of medicine which was about going digital in medicine and then most recently uh about to be published as a book called super agers It's actually about using AI to promote healthspan.

0:02:35

It has not been previously laid out like that. It's a blueprint for how we can go forward. And we couldn't do it without the current types of models with AI. And that's what makes it especially exciting.

0:02:48
Craig S. Smith

Yeah, I just saw Bill Gates at an interview talking about how someday soon within the next decade, we're all going to be accessing medical information through agents, AI agents. uh so super agers the the uh yeah give me the thesis of the book is it is it about how ai is going to spread uh knowledge and and uh or is it more about uh aging strategies or how to combat

0:03:26
Eric Topol

aging yeah so there are the three major uh age-related diseases uh heart um neurodegenerative alzheimer's and cancer they all take 20 years to incubate they all have common threads of the immune system and inflammation and now we can tell in any given individual who is at high risk by a full stack of data depth that we've never had before that's not including not just including electronic health records and labs and images but it's also including the genome proteins metabolites they get microbiome environmental exposures social determinants of health anyway for all these different layers of data the ai will tell us if you are high risk when Then pinpointing when this will show up if nothing is done.

0:04:30

And then that can be used to direct surveillance and prevention strategies. So you never have one of those three age-related diseases, which are the biggest burden of our chronic disease and killers, of course. So this is an exciting time. It's unique. it's it's momentous in many respects because we didn't have the ai that could could input ingest all this data and we didn't have the data to ingest right so um what we have now is a is a just extraordinary time to be able to help each person know especially at a younger age what's in store for them and to do these things that would help prevent at the very least

0:05:22
Craig S. Smith

markedly delay a condition yeah and that data i mean there are two issues one is uh the the privacy issue that's kept a lot of uh health care data locked up and inaccessible to ai models but also personal health data that is not necessarily digitized or or very complete longitudinal i I mean, I've moved around the country. I don't know where all my, not the country, the world, where all my data is, if it exists. How do you tackle those two problems?

0:06:03

I mean, first of all, on just more broadly, in order to train models, you need access to large populations, data of large populations. And I've spoken to people over the years about that. It seems that that's been addressed to a certain extent. But, yeah, where do you see that today and how it's going to improve?

0:06:36
Eric Topol

Okay, well, firstly, the data story that you bring up is that I've written about extensively,! Even had a book about it, The Patient Will See You Now. people should have all their data it's their data they should own it and it should be kept in a secure platform and so other countries do that just not here in the US but that's the ideal scenario because you're not going to put your genome sequencing data or your biosensor data or other layers of data into your electronic health record because we don't protect people fully for things like disability insurance and life insurance and you know various things that are not related to health insurance and the so-called gina you know discrimination

0:07:28

of people about their genetic information so we have to come up with a better plan about where all that data sits and that each person is entitled it's their data their body their that's critical now it turns out the am models that we have now um are very well suited for um supervised fine tuning for this task i mean the fact is they're multimodal uh they're now foundation um we can use of course uh domain specific agents, but no problem here with respect to the models.

0:08:07

If you were talking pre-transformer architecture, yes, but in the current environment, we even are getting these reasoning capabilities. And it's not like a lot of these things have to be outputs in seconds. We can wait minutes, hours, days, even for the best output. So the models are not the holdup. The data ownership is actually an issue that has to be grappled with. In the meantime, though, many people have been able to collect all their data, curate everything of theirs, particularly engineers and certain people, you know, patients of mine that have everything.

0:08:50

And so they're very well suited to enact this now.

0:08:55
Craig S. Smith

and um is okay so that's the personal data what about this this more universal

0:09:02
Eric Topol

data to train the models yeah it's surprising that uh it's not as big a challenge as you would expect because the it a lot of the things in medicine and life science uh we would never predicted that the models that already were appearing like in gbt4 and and llama and others really were remarkably well suited for for this uh just by having ingested everything known to mankind about medicine and um um you know the whole uh corpus of knowledge related to this So that, you know, in the work that's been done so far to look at being able to predict the arc of a person's, let's say, risk for Alzheimer's and when they would get out, we can do that

0:09:58

now. We don't need new models, in fact. So the difference now is, Craig, is that up until now, let's say you had a so-called polygenic risk score where you could go to 23ME or a whole bunch of different companies and tell you, you know, Craig, you have a risk of, it's high for, let's say, Alzheimer's disease. And the only problem with that is, well, there are two problems. One is it might not be that accurate.

0:10:26

But the bigger problem is, what if the risk is when you're 98 rather than 68? Big difference. And there was no way to be able to ascribe a time range. Now things are different. First of all, you have all these different layers that are orthogonal, that back up each one from another, looking to the same, try to forecast. I call precision medical forecasting. Like the weather forecasting, AI is completely revamping that, making it at accuracy levels that are hard to fathom how great it will be.

0:11:03

The same thing is true here. So basically the difference is you've got all these additional layers of data we didn't have, and what's really noteworthy is you can give a person's projection in time when this is going to be an issue if they don't do anything about it. Now, many of the interventions or preventive tactics involve lifestyle changes. And we know a lot of those, but most people don't do any of those or change behaviors. But we've also learned that when you have specific knowledge about yourself, the chances of you taking on some of these changes are much higher.

0:11:43

So these are now much more specifically bespoke to your situation. But by the way, it isn't just lifestyle changes that can help prevent these conditions. I mean, obviously there's surveillance, whether it's cancer surveillance with multi-cancer early detection blood tests, or whether it's surveillance for neurodegeneration with these new p-tower 217 biomarkers, which was a really big breakthrough. Each of these disease, age-related diseases, has ways we can stay ahead of it.

0:12:19
Craig S. Smith

Yeah. It just reminds me, as an aside, so this is really about prediction. Yes. I've been talking over the years to Alex Jovronikov from InSilico. I'm sure you know

0:12:35
Eric Topol

of him if you don't know. Oh yeah. No, I know him. He sends me stuff all the time.

0:12:39
Craig S. Smith

Yeah. Well, and his, you know, he's all on, uh, you know, anti-aging, uh, and that's kind of his motivation. And he's, you know, he's got a very sophisticated, uh, process for drug discovery and he does. Yeah. Uh, and there he's working on inflammatory diseases because, uh, he sees that as one of the major manifestations of aging that end up leading to death.

0:13:18
Eric Topol

Yeah, fibrosis.

0:13:20
Craig S. Smith

Yeah. Have you looked at, in the book, do you look at using this technology to develop drugs to target specific diseases uh of uh that are endemic to aging yeah so this is um i do review

0:13:41
Eric Topol

all the different strategies uh that are now being pursued um and you know everything from uh partial epigenetic reprogramming to you name or you know different repair um like what in silico medicine is on to with pulmonary fibrosis. You know, I review all that, but basically the conclusion is these are years away, if ever. You know, things like senolytics to take out our senescent cells in our body, but they can't tell the good senescent cells from the bad senescent cells.

0:14:15

And a lot of these things, you know, induce cancer in some organisms. So they're risky, They're iffy, they're off in time, but today what we can achieve is using AI tools and rich data, deep data for each person to forecast like we've never been able to do before. And so one of the biggest breakthroughs were these so-called organ clocks. So where Alex and I and many others in the anti-aging field converge is there have been dramatic advances in the science of aging.

0:14:54

And what is an outgrowth of that are these things, these molecular clocks, like epigenetic clocks, like the Horovath clock, where you look at methyl groups on the DNA. And there's also organ clocks. From a tube of blood, you can get 11 ,000 plasma proteins. It'll tell you which organ. So I'd say, Craig, all your organs are great, but it turns out your heart is, you know, seven years accelerated aging, which tells us right away, you know, that's what we got to zoom in and for you.

0:15:26

So we're seeing tools that we never had either breakthrough tests about the science of aging. It's not about the drug. It's about being able to, you know, clock a person, a person and their organ systems, including their immune system. We never had that before. That's what's different right now. And with these different proteins and assays, we can say, hmm, we measured it this year, we measured it, you know, this year, all that means for you to be worried about this, it's if you if you don't really go full court press, at age, you know, whatever 71, this is going to hit you, you're going to start having symptoms.

0:16:06

So with that point that we have 20 years to undo the natural history of risk, it's a it's an, you know, this is a whole different strategy. The book is about a different strategy than the one that these companies are pursuing, like Altos Labs and Unity and in silico, you know, there's 50 of these anti-aging companies, right? I'm saying And good, good luck to them. I hope they're successful. But I have a different plan that's not risky, okay?

0:16:40

Because preventing diseases is a dream in medicine that's been a fantasy that's been around for, you know, multiple millennia. Now we have a chance to do something about it. Yeah.

0:16:55
Craig S. Smith

How much of this is productized at this point?

0:17:00
Eric Topol

Everything's like, yeah, you're right. Everything's piecemeal. So you got to go here to get your organ clock. You got to go here to get your, your epigenetic clock. You got to go here to get your metabolome, you know, here to go to get your gut microbiome. So it isn't, the package isn't, but you could do it. You can do it. It's just that the, the AI tool is separated from each of the layers of data. It's just a matter of time when this comes together.

0:17:30

Your point is a good one, Craig.

0:17:33
Craig S. Smith

Yeah. I just wrote a piece for Forbes about MCP. I'm not going to remember what it stands for, but this Anthropic developed standard protocol for connecting AI systems to disparate data sources or disparate tools sort of thing.

0:17:57
Eric Topol

This one is being cracked every day with multi-omic. So in the life science field, which is what this is really converging with, they are already looking at every layer of DNA, RNA, single sequence, single cell sequence, nucleus, and all the other ones I've mentioned. They've already figured out how to do all that. And that's exciting because that's just part of this. all you got to do is you know add in a couple of traditional medical pieces like the electronic records which contain labs and images and you're there yeah uh in the book do you

0:18:35
Craig S. Smith

go through how somebody could collect all of this data because for the lay person i would i mean just the the list that you mentioned uh i don't know anything about did you say melanome Oh, the metabolome. Metabolome. Yeah. I mean, I don't know what that is, where it is, how I could find it.

0:18:59
Eric Topol

Yeah. Well, there's a company, Metabolon, that does that and other companies as well. I don't go through that step by step. I just basically trying to say, look, folks, we're going to a new era where you're going to know your risk. And I lay out, you know, what are the layers of data, how we're going to do this. In the next year or two, we'll see the companies that have the whole package. Right now, there's these companies pitching data for longevity.

0:19:30

And I called them out. I wrote a sub stack about that recently. You know, these companies that are selling supplements. I mean, this is not my science. But they have the right idea, okay? Because some of them are assembling these different layers of data already. They're not using AI. Sometimes they say on their website they use AI, but no, they're not real AI. So we're already seeing the budding. You know, there's several companies that this is in their sights right now, and it's not going to take long for them to adapt to the opportunity, which, you know, this is a very clear path to achieving something we've never been able to do before.

0:20:17

Our ability to give a person's risk assessment of a disease has been rudimentary at best, but actually incredibly weak and inaccurate. And it's our most important thing is that we should be knowing well in advance what we have to prevent and how we do it.

0:20:38
Craig S. Smith

Yeah. And one thing you said, I was thinking as you were talking, you know, I've looked a lot at uh ed tech and i've spoken to a couple of companies that have an assembly of algorithms and uh and one of the things that struck me is most promising is that you can have a knowledge tracing algorithm that that tracks the knowledge of a student as the student studies provided that they're interacting digitally. And then you can have a prediction algorithm that predicts the student's score in an exam or in a course.

0:21:25

And then you can have a recommendation engine that recommends stuff to fill in the knowledge gaps. And when you put it all together, I mean, theoretically, the student, if he follows the recommendations, can see his predicted score going up. And that's a huge motivator. It could be the same thing with...

0:21:46
Eric Topol

Same exact model type of... I agree.

0:21:49
Craig S. Smith

More compelling because it's your lifespan that you're increasing, not...

0:21:56
Eric Topol

Yeah, exactly. And just to add to it, so you know the likes of Jeff Hinton, Demet Pesabas, Mustafa Suleiman, all three of them reviewed the book. And they all thought this is, you know, extraordinary. They supplied, you know, endorsements, not, you know, because they see that, you know, actually both Demis and Jeff have said that the most important ever use of AI will be to improve our health. And this is, I think, unless I don't know, Craig, but I don't think anybody has laid out how we're going to do this yet.

0:22:33

This is kind of that's why I'm excited about it. and they were excited about it. So, you know, we have now a way, it's very similar to what you just described in education. Of course, it's a totally different application. It's a little more complex, but it's ready to go. It's not going to take long to get there.

0:22:57
Craig S. Smith

Building multi-agent software is hard. Agent-to-agent and agent-to-tool communication is still the Wild West. How do you achieve accuracy and consistency in non-deterministic agentic apps? That's where agency comes in. A-G -N-T -C-Y. The agency is an open source collective building the Internet of Agents. And what's the Internet of Agents? It's a collaboration layer where AI agents can communicate, discover each other, and work across frameworks. For developers, this means standardized agent discovery tools, seamless protocols for interagent communication, and modular components to compose and scale multi-agent workflows.

0:23:48

Build with other engineers who care about high-quality multi-agent software. Build with other engineers who care about high-quality multi-agent software. Visit agntcy.org and add your support. That's A-G -N-T -C-Y dot O-R -G. Yeah. Are you free to mention companies that you think are on the right track in coming out with an application?

0:24:21
Eric Topol

Well, I reviewed all of them that are out there. um and you know there i'll just pull up the chart i made um from the ground truth that i did uh one sec here if you can bear with me um sure uh yeah i just put it out a week ago i called it the business business of promoting longevity and healthspan basically the 12 companies there was one that started this years ago a decade ago called human longevity they get total body mri and genome sequence this was before there was any ai got all these labs and whatnot that company is just basically not almost non-existent now charging 25,000 to come and have all these things done that's

0:25:10

not that's a no-brainer not going to work. Function Health, they do 100 lab tests. That's it. So that's not exactly what we're talking about. And of the ones, Life Force is, I think, on the right track. Let's see, going down the list, Fountain Life is trying to get a whole lot of tests. Actually, when you look at them, they have the right idea that you need more layers of data, but none of them are getting the right data.

0:25:45

I wrote about that in the post. They have this idea that, oh, if I know much more data about a person, I can guide them. They're just not getting the right data. And none of these companies have a significant AI effort yet. But some of them have raised immense capital. Like, for example, Function has a valuation of $2.5 billion already. It has 50 ,000 members and a wait list. Neco Health has 100 ,000 people on a wait list.

0:26:18

So people want this. Yeah. Okay. But they're a little clueless about they're not getting what they should get.

0:26:25
Craig S. Smith

Yeah. Are you advising?

0:26:27
Eric Topol

I mean, you obviously are deep in this. Not advising any of them. I don't want to be conflicted.

0:26:33
Craig S. Smith

Well, why you have a deep knowledge of AI and you have a deep knowledge of medicine. Have you thought about doing exactly what we're talking about?

0:26:47
Eric Topol

Yeah. Okay. So the Function Health, the one that has this massive valuation, one of the principles is a doctor named Mark Hyman. he flew here, right here sitting in my office, and he offered me to, you know, be part of the company and, you know, get all sorts of financial incentives. I told him, Mark, I just can't do that. Because if I do that, then people will read this book, or see me as, you know, I'm doing this for financial gain, just like they sell supplement, which I don't agree with.

0:27:19

That's another reason i wouldn't do it right yeah so basically i can't for me it's much more important to put out the ideas and not have any profit motive whatsoever yeah yeah yeah well i didn't mean as much as

0:27:33
Craig S. Smith

as profit motive i mean obviously you're you've had a financially lucrative career uh but just as you you see the problem you see the solution you have the knowledge uh and certainly the contacts to pull together a team that that could solve the problem well i i just wanted to

0:27:56
Eric Topol

get it done and like i have done in the other previous books i gave a lot of people the ideas right i so many people have written me or come visit me and tell me you know i built my company because of what you wrote. And that's kind of what I'm hoping is other people can execute. Here's the recipe, here's the blueprint, whatever you want to call it. And that's, I think, how it's going to get done.

0:28:20

Now, the reason I mentioned these companies, they already have a head start. They have revenue. They have, you know, some of them have pretty strong participation, memberships, whatever. So I'm perfectly happy to see them pivot, do this right, get there, where we eventually all will be i don't want this to be a thing just for the affluent either yeah in fact the people who need this the most are the ones who can't access or afford it yeah uh how much

0:28:49
Craig S. Smith

of this i mean you you understand the relevant data how to get the relevant data how much of that have

0:28:55
Eric Topol

you done yourself uh most of it so in the book i got uh an immunome the beginning of an immunome from a company, Infinity Bio, Johns Hopkins spinoff, which is another essential part of the layers of data. I've had most of the other layers of data. So I have done this, and the only risk of the big three that I'm facing is the cardiovascular risk. And so now I know what I got to do. I'm going to get my LDL down to the lowest level and 10 other things that I got to do.

0:29:32

But there are things that, you know, turning to much better sleep health, getting much better deep sleep and many other things that we can do once we know what we're after. Now, if you find that you don't have a risk for one of these big three diseases, well, you're lucky. Right. Doesn't mean you should go out and go into self-destruct mode, but you're lucky. The point is most people, one of them, if not more than one, have vulnerability.

0:30:03

And the question is the cutoff. You know, top 5%, top 10%. That's something that is still going to be debatable for years to come. What is risk, right?

0:30:16
Craig S. Smith

And you were talking about the timing, predicting the timing of risk. How accurate do you think that can be?

0:30:25
Eric Topol

i mean yeah i think it can be it's hard to get it on one shot um but if you have a person that you see is at high risk by the time you do a second assessment then you have it so if you have just two points on the curve uh you'll know what's about the brain amyloid accumulation what about microscopic cancer showing up what about atheroma forming in arteries so yeah it doesn't take it's hard to do in a single point basis, but two data points separated in time by six months or a year, and you nailed it.

0:31:02

The key is that first baseline to determine the risk and then use the second

0:31:08
Craig S. Smith

point to determine the timing. Yeah. And for the timing, for example, uh let's pick one cancer yeah yeah uh you know you look at your family history you look at presumably different biomarkers uh maybe your your personal genome uh what would what would the prediction be that that in three years in 15 20 years you you have an uh you know a 95 chance

0:31:45
Eric Topol

i mean what does the prediction look like okay well the 95 that's what we were talking about earlier top 5% that would be 95 or very high risk that is um you know somewhere i'm thinking you know most people if they're not in the top five or 10% they they're not going to really, that's really where you draw the threshold. That's where some medical health systems, like for example, Mass General Brigham has drawn the threshold for genetic risk.

0:32:13

So let's just say we're talking about top five or 10%. We're not likely to get out a readout that, you know, this is going to happen in 18 years. But certainly, you know, when it's more proximal, like three to five years, that would be the way you show up. Now, how do we get this? Well, it turns out, and i make a really important point early in the book we have over estimated the family history genetic story okay now for cancer it's more of an issue than it is for the other two because if you have any of these uh cancer predisposition genes we're not just talking about braca genes but other genes that puts you in a different strata

0:32:56

of risk but the point being here is that there are many other factors like the level of your body inflammation, those organ clocks, again, your total body aging clock. If you're seeing things that are out of kilter, and then you get a multi-cancer early detection test, the chance of that being abnormal. See, today, what's amazing, these tests are advocated for people age 50, period. Now, talk about a senseless way to use a test, you know, out of 1000 people that get the test now, 995 are negative.

0:33:37

Okay, but when you use that test, when you have these other things that are suggesting increased risk, then the yield is so much higher. I mean, this is Bayes' theorem. So that's how we get the risk of cancer nailed down. And then of course, if there's an organ clock that's already showing up, You can start to, and you're going to get images, of course, like a total body MRI if you really, but the multicenter cancer detection test already with AI can tell you which organ is lighting up most of the time, very accurate actually.

0:34:11

So the cancer story I think is not that hard to see through. As long as you don't say it's just the genes, that's our biggest problem is we think we have this kind of. over emphasis about our family history and this kind of dooms, impending doom thing that we live our whole life. My father had a heart attack when he was 50. And you think about that like all the time. We got to get that out of our system because that just doesn't really play out.

0:34:43

We did a so called WELDERLY study, we called it here. 1400 people lived through past age 85, never sick. none of these diseases. We sequence whole genome, all of them. And what did we find? Very little, almost nothing. So the secret in the genes thing is not so, there's not that much to it. There's a little, but not much.

0:35:11
Craig S. Smith

Yeah. Let me think, where do we go with this? The conclusion of the book then is that there's this promising technology that's here and there's ways to get the data to make the technology useful. What are you, this is, I would presume, not only for AI technicians but for general readers. What is the recommendation? I mean, what is the book telling us to do?

0:36:04
Eric Topol

Well, there's a whole chapter on these lifestyle things that, you know, it'd be great if we adopted all those now, right? Because, you know, without even knowing your risk for a particular condition, it'd be good. but I review all the data, you know, everything from, you know, protein and ultra processed foods and environmental hazards, microplastics, I mean, all this stuff, each of us have at least some potential to affect, right. And then I get into this, what I call, you know, brimming with optimism, that we have a much more, you know, exciting way to go forward in medicine, to be able to and be informative early in a person's life and i mean it's never too late but uh for

0:36:50

people of our age but even better is you know somebody in their 40s or 50s yeah or younger even but the point here is that um there's a new path forward that i think is transformative in medicine we couldn't do it without uh multimodal ai models that exist today and are keep getting better and we couldn't do it without the layers of data that were discovered largely through the science of aging. But a lot of people are using that, you know, of course, for companies to come up with drugs.

0:37:23

Yeah, and I'm saying, No, no, no, we got it for a different purpose now. And let's stamp out age related diseases. Let's do it. So that the book leaves the lay reader, I hope with an optimistic view, in otherwise pretty dark times for life science right now when, you know, our funding is getting gutted every day. People are getting laid off from NIH, FDA, CDC. So on the one hand, the world isn't doing too well right now, but here's something that's hopefully exciting to read about, know where we're headed.

0:37:58

I mean, each of the books I've written, this is my fourth book, probably my last book, is about the future of medicine. And this one is the most exciting yet. This one, I think, is something we can really make a huge difference in the future.

0:38:14
Craig S. Smith

Yeah. You know, there's a lot of talk about personalized medicine and with, you know, the ability now to edit the genome and create novel proteins. what's your view just generally i know this is not what your book's about but about the promise of precision personalized medicine becoming widely available yeah i'm really glad you asked that

0:38:52
Eric Topol

craig because this is the nuts of it right here um we haven't really done it you know here and there we did a little with oh well you have this mutation and cancer we're going to treat you with this drug or you know but precision medicine largely has been a disappointment it's been talked about a lot but we haven't achieved it um this is our segue this is our our way to get there because we didn't have the depth of data so when we talk about precision individualized medicine we couldn't really define that person well we're still missing the immunom data which is one of the most, if not the most important layer, but there are companies that are pursuing

0:39:37

that, you know, intensely right now. And I tried one of them and there's a couple others, a group at Stanford that plans to spin out of a company that does B and T cell sequencing that looks really exciting. So we just didn't have the goods to do it. And it was all talk and no action largely. Now we have the goods and I hope we have the action.

0:40:02
Craig S. Smith

I don't want to keep you too much longer, but you also mentioned epigenetic research or strategies. I had Sebastiano Vittorio Sebastiano on the podcast years ago, who works on using Yamanaka factors to roll back the aging of cells. And you mentioned the risk is that a lot of this leads to cancer. But what do you feel about that? And you mentioned organ-specific, or I don't remember the word you used, but treating, you know, specific groups of cells epigenetically.

0:41:02
Eric Topol

Oh, senescent cells? Yeah, so the first one you mentioned is, you know, huge bets have been put on this. many companies are pursuing the yamanaka factors right and you know you brief exposure to them and you can turn a an old mouse into a young mouse i mean it's like wow you know um but the problem is is that you can't just give these you know a shot to somebody with excuse me you give then you have a real risk of tumor so what's fascinating is these companies have figured out you just can't give it like you can give it to a mouse.

0:41:44

So what they're trying to do is figure out how can you do a human trial? So one of the companies is thinking about going in the knee for people who have horrible knee arthritis and otherwise need a knee replacement. Another company is putting it in the eye. You know, so they're not achieving the fountain of youth here. They're going to try to do it in a limited compartment test zone, if you will. Right. um it's going to be dicey because we've already learned that the exposure to those powerful factors yamanaka yamanaka transcription factors well that's a really risky strategy uh it it's like a reward's really high but you know putting that a human we're gonna it's gonna take a

0:42:27

long time before we see a whole human get exposure to those um you know intravenously or whatever uh systemic pathway. The other companies, like I mentioned, that these senescent cells that are thought to be bad actors because they secrete very noxious proteins and they rev up inflammation in the body. The problem is some of them are really good and we don't have a way to say just go after the bad actors. Leave the good ones that are promoting healing and doing lots of good things and um you know so we don't have smart ways to eradicate the bad cells and if you go through each of these and there's at least 10 different ideas uh which i go through in

0:43:13

the book they all carry significant risk they're all some years away and i hope that they're successful but they're not here and now yeah what we've been talking about in this conversation is a kind of here and now thing right yeah it can be done today or imminently those are years off and maybe never i i hope they're successful each one of them has some good ideas um but we'll see yeah another

0:43:43
Craig S. Smith

uh thing about uh sort of the aging debate that uh you hear people talk about and i'm just curious what your view is. Of course, I want to live much longer than I'm slated to live. I tell my wife, gosh, I wish I had 40 years instead of 20 years. But if everybody added five years to their lifespan, the demand for resources would quickly be overwhelming. I mean, how do you balance, you know, human desire with...

0:44:33
Eric Topol

Yeah, well, first say the desire really isn't for lifespan. It's for healthspan, right? I mean, if they're demented, they don't really want to live longer. Yeah. So you're right. I mean, it's hard to meet a person when you talk about would you like to live healthier, you know, long life. And, you know, rarely would you say no. You hear someone say no. So, you know, the demand will be high. And, you know, what we're talking about here is largely software, because these tests that get you those additional layers, they can be done inexpensively.

0:45:09

You know, every one of these is, you know, it's below $100, $50, you know. So even if you take the whole package, it's not like putting somebody in a total body MRI, which now you're getting into the thousands. So the interesting thing is it may get done in other countries before the U.S. because we have terrible, perverse incentives here. We have these insurance companies that they don't think they're going to have you next year. so they only care about immediate gratification right whereas if you're in other countries like you know i was asked to review the national health service in the uk they're representative of most other uh rich countries which is they take care of all their people

0:45:54

yeah for life so they're going to be the countries that make these uh you know basically uh implement uh and here it will be more likely to be, you know, if you're affluent and you, you know, the demand, I do think the demand will ultimately be high, you know, some years out from now when this is widely available. But we're not in a good position in this country to make it equitable or accessible relative to other countries because they can see a small investment can lead to a huge downstream reductions of cost, no less healthier lives.

0:46:33

Yeah.

0:46:34
Craig S. Smith

Yeah. Okay. Well, this is just fascinating, and I'm going to go buy the book right now on Amazon. It's coming out May.

0:46:46
Eric Topol

I could send you the PDF, if you like, instead.

0:46:49
Craig S. Smith

I don't mind pre-ordering.

0:46:51
Eric Topol

I'm waiting to get the actual hard copy tomorrow or Thursday, finally. And I think it was Stephen Morrow that got us together. Is that right?

0:47:04
Craig S. Smith

I'd have to go back and check. Oh, okay.

0:47:06
Eric Topol

I thought maybe he was the one that you said, you got to talk to Craig. I don't know.

0:47:10
Craig S. Smith

Well, it may very well have been, yeah.

0:47:13
Eric Topol

Anyway, it's been a joy, Craig. I really enjoy. You asked a lot of great questions that I think are really spot on.

0:47:22
Craig S. Smith

Yeah. Well, I'm probably, once I get the book, well, how about this? How about you send me the PDF and I promise to buy it? I just, my wife writes, and I always think people, if they're interested in a book, they should buy it, not get a free copy. But if you could send me the PDF, I'll write something. I'm a contributor at Forbes. Not that that gets a lot of traction, but...

0:47:53
Eric Topol

Oh, great. Can you send me your email address? Yeah, I will. I'll do it right after this. Excellent. All right. We'll get it off to you. And it's been a pleasure to talk with you.

0:48:03
Speaker 3

AI is everywhere right now, but with all the buzz, how do you cut through the noise and focus on what really matters? If you're looking to dive deep into the big questions shaping AI's role in business today, you need to tune in to where AI works. conversations at the intersection of AI and industry brought to you by the Wharton School in collaboration with Accenture. Each episode cuts through the hype, blending cutting edge research from Wharton professors with real world case studies.

0:48:30

You will discover how leading companies are leveraging AI to upskill their teams, boost productivity and streamline operations. And you will hear directly from executives and industry pioneers who are implementing AI in their businesses today. No fluff, just practical insights. Listen to Where AI Works Now on your favorite podcast app and get the strategies that matter most for today's business leaders.